Tüdőrák: vizsgálatok itt: Lengyelország
116 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Bialystok, Bydgoszcz, Cracow, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Lodz, Lublin, Olsztyn, Poznan, Przemyśl, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisNot yet taking people in LengyelországClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Bialystok, Cracow, Lodz, Lublin, Poznan, Siedlce
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 2. fázisNot yet taking people in LengyelországA Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
- Where
- Olsztyn, Tomaszów Mazowiecki
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Puma Biotechnology, Inc.
See details and how to joinNCT07465757 · EU 2026-525382-47-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Cracow, Gdansk, Kielce, Lublin, Olsztyn, Otwock, Poznan, Skorzewo, Torun, Warsaw
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1. fázisTaking peoplePhase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 214 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00 - 1/2. fázisNot yet taking people in LengyelországFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Gdansk, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - 1/2. fázisBefejeződöttKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00 - No phaseBefejeződöttKEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Where
- Gdansk, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 1065 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165798 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Lodz, Olsztyn, Poznan, Rzeszów, Warsaw
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 1/2. fázisTaking peopleStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Where
- Gdansk, Lodz, Olsztyn, Warsaw
- Életkor
- 18 év and over
- People
- 364 worldwide
- Run by
- Synthekine
See details and how to joinNCT05098132 · EU 2025-522632-14-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Bydgoszcz, Lodz, Lublin, Poznan, Warsaw, Wilkowice, Wroclaw
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 2. fázisNot yet taking people in LengyelországDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Cracow
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Olsztyn, Poznan, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Bydgoszcz, Lodz, Lublin, Poznan, Warsaw, Wilkowice, Wroclaw
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisTaking peopleA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Koszalin, Lodz, Olsztyn
- Életkor
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Bialystok, Bydgoszcz, Gdansk, Kielce, Koszalin, Lublin
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - 2. fázisTaking peopleA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Where
- Lublin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00 - 2. fázisTaking peopleTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Where
- Lublin, Poznan, Prabuty
- Életkor
- 18 év and over
- People
- 131 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Bydgoszcz, Gdansk, Konin, Lodz, Lublin, Poznan
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - 3. fázisBefejeződöttStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Cracow, Lublin, Przemyśl, Tomaszow Mazowiecki
- Életkor
- 18 év and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - 3. fázisNot yet taking people in LengyelországA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Katowice, Lodz, Opole, Przemyśl
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Lodz, Poznan, Rzeszów, Siedlce, Stupsk, Warsaw
- Életkor
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - 3. fázisTaking peopleA Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Bialystok, Katowice, Lodz, Lublin, Poznan, Przemyśl, Siedlce, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00 - 2. fázisTaking peopleTrial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
- Where
- Lublin, Poznan, Prabuty
- Életkor
- 18 év and over
- People
- 107 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07098988 · EU 2024-516792-32-01 - No phaseTaking peoplePRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Gdansk, Olsztyn
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253